Naples, FL, November 1, 2022
Spirify Pharma Inc., a developer of next generation drugs in pain and mental disorders, is excited to announce a research collaboration with WeLab Barcelona to advance their proprietary class of analogs of hydroxynorketamine. “The collaboration with the WeLab team is expected to provide first data to support the proposed unique mechanism of action (MoA) of our novel molecules via mTOR activation and D-serine modulation.” states Irving Wainer, Spirify’s co-founder and Chief Scientific Officer and main inventor on the Spirify patents.
Naples, FL, October 12, 2021
Appointment of experienced pharma executive further strengthens Spirify’s leadership team. Spirify Pharma, Inc. (“Spirify”), a pharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in CNS diseases, today announced it has appointed Alexander Kraus, PhD to the newly created position of Chief Business Officer. Dr. Kraus’ role will include business and corporate development, licensing, and strategic planning.
Naples, FL, December 12, 2021
Spirify Pharma, Inc. (“Spirify”), a pharmaceutical company utilizing a platform approach for a class of proprietary modulators of D-Serine levels in the CNS, is announcing its participation in the the BIO Partnering Conference during JP Morgan week from January 10-14, 2022.
Naples, FL, July 27, 2021
The Company Raises Seed Funding to Expand Its Operations Manufacture and Test It's Lead Compounds.
Spirify Pharma, Inc., a pre-clinical stage pharmaceutical company dedicated to developing novel therapies for CNS diseases including pain, depression, and certain neurodegenerative diseases, announced today that it has successfully closed its seed funding round.
Naples, FL, September 4, 2020
Spirify Pharma Inc., a pharmaceutical company dedicated to transforming the way pain is treated -- without opioids -- will present a poster at PAINWeek 2020, outlining its innovative approach. Developing analogues of a ketamine metabolite - Hydroxynorketamine (HNK) - Spirify aims to effectively and safely reduce intracellular D-Serine levels. D-serine is a potent co-agonist for the NMDA receptor, which is central in the initiation and persistence of chronic pain.